Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Merck & Co., Inc. : WSJ BLOG/Health : Experimental Drug Might Open New Category of Sleep Aid

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/13/2012 | 06:17pm CEST

(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.)

By Christopher Weaver

Patients with severe insomnia taking a Merck experimental sleep drug drifted off faster and slept longer than those taking placebos in two clinical studies discussed at a Boston sleep conference today.

The drug, suvorexant, opens a new category of sleep drugs by blocking orexin, the brain's chemical emissaries that promote alertness. Merck says it plans to apply for FDA approval later this year.

Both of Merck's trials included more than 1,000 patients with insomnia. Patients whose sleep troubles were caused by other medical problems weren't included in the studies. The results were reported after three months of taking the drug or a placebo.

Those taking suvorexant reported falling asleep 25.7 minutes faster than usual, and sleeping an hour longer in one trial. Merck's researchers also observed patients in sleep labs and determined that patients taking the drug fell asleep 36 minutes faster than usual, while those taking placebos fell asleep 26.6 minutes faster.

The second trial also showed the drug helped people sleep longer, though people in that group who took it didn't fall asleep faster than patients taking placebos.

The findings were presented at the Sleep 2012, an annual meeting of sleep scientists and health providers.

The U.S. market for sleep drugs sagged to $1.85 billion in 2011, down about 8% from the prior year, according to IMS Health, a health-care-information company. The decline was driven by generic competition for key sleep drugs.

Suvorexant could offer a new option for patients with chronic insomnia who routinely need sleeping pills, Merck hopes. Other sleep drugs on the market, such as Ambien, keep patients asleep for about two thirds of the night, while suvorexant provides longer rest, Dr. Darryle Schoepp, Merck's vice president in charge of neuroscience, said in an interview last week.

For decades, a series of sleep drugs have focused on "shutting down the whole brain in maybe a less natural way," Schoepp said. So-called Gaba agonists, such as Ambien, Sonata and Lunesta, which are often prescribed to be taken as needed, have been shown to have side effects, including sleep walking, in a small fraction of patients.

Merck says patients who routinely need sleep aids will better tolerate suvorexant, which also performed well in a cohort of patients Merck followed for a full year. In contrast to older drugs, Schoepp said, Merck's research showed that patients taking suvorexant experienced normal sleep rhythm.

The study showed suvorexant's main side effects were headaches and morning drowsiness.

 
 -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com. 
 

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
04/20MERCK AND : Advances Clean Energy Goals with Invenergy
AQ
04/20MERCK AND : Announces First Phase Three Studies for PCV-15 its Investigational P..
AQ
04/19MERCK AND : P&G Boasts Better Bottom Line
AQ
04/19MERCK AND : Biothera Pharmaceuticals Presents Translational Data from Ongoing Cl..
AQ
04/19LEAP THERAPEUTICS : Presents Nonclinical and Clinical Data on DKN-01 at AACR 201..
AQ
04/19MERCK AND : AstraZeneca and Merck - Updated Overall Survival Data for LYNPARZA i..
AQ
04/19MERCK AND : KEYTRUDA plus Pemetrexed and Platinum Chemotherapy Reduced the Risk ..
AQ
04/19MERCK AND : KEYTRUDA Reduced the Risk of Disease Recurrence or Death by More tha..
AQ
04/19MERCK AND : Nuevo tratamiento contra cáncer de pulmón da buenos resultados
AQ
04/18ASTRAZENECA : New protein complex sensitizes cancers to PARP inhibitors
AQ
More news
News from SeekingAlpha
04/19Novartis Q1 results weigh on pharma stocks 
04/19DYNAVAX : Assessing The Underlying Fundamentals Of A Big Winner 
04/18I'm Buying Bristol-Myers Down Near 52-Week Lows 
04/18ASLAN Pharmaceuticals Updates U.S. IPO Plans 
04/183 THINGS IN BIOTECH, APRIL 17 : Lung Cancer Madness 
Financials ($)
Sales 2018 41 873 M
EBIT 2018 13 847 M
Net income 2018 8 764 M
Debt 2018 13 077 M
Yield 2018 3,31%
P/E ratio 2018 18,30
P/E ratio 2019 15,31
EV / Sales 2018 4,11x
EV / Sales 2019 3,94x
Capitalization 159 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 67,6 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY4.55%158 813
JOHNSON & JOHNSON-8.71%342 627
PFIZER1.13%217 064
NOVARTIS-6.21%213 465
ROCHE HOLDING LTD.-12.17%193 713
AMGEN-1.35%117 021